论文部分内容阅读
60例应用口服降糖药血糖控制不理想的T2DM患者随机分为甘精胰岛素组(n=30)采用每晚8点注射来得时,当某餐餐后血糖控制不良时,即加用诺和锐。强化治疗组(n=30)采用三餐前30min皮下注射诺和灵R,每晚10点注射诺和灵N。目标为空腹血糖≤7.0mmol/L和餐后2h血糖≤10.0mmol/L。结果治疗后两组FBG、P2BG均较前明显下降,P2BG及血糖达标时间比较无统计学意义(P>0.05),但甘精胰岛素组FBG低于强化治疗组,低血糖事件明显少于强化治疗组,每日注射4次胰岛素患者明显少于强化组,且患者坚持用药时间明显长于强化治疗组(P<0.05)。结论甘精胰岛素联合餐时超短效胰岛素可以良好地控制高血糖,且低血糖发生率低。
Sixty patients with T2DM who did not control their glycemic control with oral hypoglycemic agents were randomized into insulin glargine group (n = 30) and received nocturnal injection at 8:00 p.m. sharp. Intensive treatment group (n = 30) norepinephrine R subcutaneous injection of 30 minutes before the three meals a night, injection of Novolin N 10. The goal is fasting blood glucose ≤ 7.0mmol / L and postprandial 2h blood glucose ≤ 10.0mmol / L. Results After treatment, FBG and P2BG in both groups were significantly lower than those in the two groups before treatment, and there was no significant difference between P2BG and glycemic control (P> 0.05). However, FBG in glargine group was lower than that in intensive treatment group, and the incidence of hypoglycemia was significantly less than that in intensive treatment group Group, four times daily injections of insulin was significantly less than the intensive group, and patients insisted on medication was significantly longer than the intensive treatment group (P <0.05). Conclusion Glargine and mealtime ultra-short-acting insulin can control hyperglycemia well, and the incidence of hypoglycemia is low.